Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada

Author:

Douglas Conor M.W.ORCID,Grunebaum Shir

Funder

Social Sciences and Humanities Research Council of Canada

Publisher

Elsevier BV

Reference47 articles.

1. Advanced therapy medicinal products for rare diseases: state of play of incentives supporting development in Europe;Farkas;Front Med (Lausanne),2017

2. From sandbox to pandemic: agile reform of Canadian drug regulation;Vural;Health Policy (New York),2021

3. Enzyme replacement therapy for Anderson-Fabry disease;El Dib;Cochrane Database System Rev,2016

4. The safety of agalsidase alfa enzyme replacement therapy in Canadian patients with Fabry Disease following implementation of a bioreactor process;Khan;Drugs R D,2021

5. Who should be given priority for public funding?;Bae;Health Policy (New York),2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3